Medical Director, Molecular Diagnostics Laboratory at Diagnostic Laboratory Services, Inc.
BIOGRAPHY
MAY 24, 2022 11:00 AM PDT
Next-Generation Sequencing (NGS) Assessment of Homologous Recombination Deficiency (HRD): Expanding NGS Data to View Events Associated with Genomic Instability
Speakers
-
Zan Halford, M.S. SMB(ASCP)CM,
Medical Technologist, Diagnostic Laboratory Services, Inc. Aiea, HawaiiBIOGRAPHY
Event Date & Time
Date: May 24, 2022
Time: 11:00am (PDT), 2:00pm (EDT), 7:00pm (CEST)
Abstract
NGS tumor profiling has become the mainstay of modern cancer therapy. Several NCCN-guided and FDA-approved therapies are currently on-market targeted by tumor genotype, and research is ongoing to identify other genomic alterations that can be used for stratification and drug development. This webinar describes an approach to genomic discovery that processes NGS data via NxClinical software from Bionano Genomics to assess solid tumors for genomic instability states associated with HRD.
Learning Objectives
- Be able to describe homologous recombination deficiency in the scheme of DNA damage and its role in cancer therapy, focusing on high grade ovarian epithelial cancers
- Summarize the method of software solutions to view HRD genomic scars and describe the scoring method of HRD assessment
- Describe the performance and limitations of NGS data in measuring chromosomal structural variants
Webinars will be available for unlimited on-demand viewing after live event.
You May Also Like
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
Loading Comments...